Services
What we offer
Treating Depression
Over 21 million Americans are affected by Major Depressive Disorder. Regrettably, nearly half of those who undergo treatment with antidepressant medications do not experience a sufficient response. The FDA defines Treatment-Resistant Depression (TRD) as a condition where patients fail to adequately respond to two distinct antidepressants of appropriate dosage and duration.
The Treatment
SPRAVATO is a nasal spray containing Esketamine for treating depression. Patients self-administer the spray under a healthcare professional's supervision, who monitors them for 2 hours per FDA guidelines. The treatment has two phases: Initiation (twice a week for four weeks) and Maintenance (weekly or biweekly). Our patient pods offer a comfortable setting with HD TVs and reclining chairs. Studies show SPRAVATO provides positive results without long-term serious side effects, abuse potential, or significant weight gain or sexual side effects.
The Evaluation Process
Spravato Treatment Evaluation at Innovative Psychiatric Services:
Fill Out Initial
Questionnaire
Provide medical history, symptoms, and past treatments.
Psychiatric
Evaluation
Clinician confirms diagnosis for Spravato suitability.
Develop a Personalized Treatment Plan
Collaborate on dosage and complementary therapies.
Insurance & Financial Coordination
Assistance with coverage, costs, and payment plans for various providers.
Patient
Education
Understand the Spravato process, side effects, and safety measures.
Treatment
Commencement
Begin Spravato sessions at our clinic with continuous monitoring and adjustments.
